Lexaria Bioscience Corp. (LEXX) has been given the go-ahead by an independent third-party ethics review board to begin a new human pilot study investigating GLP-1 drugs and DehydraTECH.The GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.DehydraTECH is the company's proprietary drug delivery technology designed specifically for formulating and delivering lipophilic (i.e., fat...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.